Delivering the highest quality care in accordance with best practice is
a fundamental tenet of diabetes and glycemic management at Grady
Hospital of Atlanta, Georgia, which is why in 2016, the academic
medical center chose to standardize its approach and elevate both safety
and efficacy by implementing Glytec’s eGlycemic
Management System® (eGMS®) in its intensive
care and step-down units. A retrospective analysis conducted by Drs.
Guillermo Umpierrez and Jordan Messler, and presented at the American
Diabetes Association 79th Scientific Sessions, observed that outcomes of
patients managed with eGMS® were consistently superior to
those managed with a standard protocol. Outcomes measured over a
two-year period (December 2016 to December 2018) included incidence of
hypoglycemia, incidence of hyperglycemia, target glucose attainment, and
reduction in admission-to-discharge blood glucose.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190618005878/en/
Study conducted by Dr. Guillermo Umpierrez, Professor of Medicine in the Division of Endocrinology and Metabolism at Emory University School of Medicine and Chief of Diabetes and Endocrinology at Grady Hospital, observed that outcomes of patients managed with Glytec’s eGlycemic Management System® were consistently superior to those managed with a standard protocol. (Photo: Business Wire)
|
Representative Outcomes From Study |
||||||||||||
| Outcomes |
Glytec eGMS® |
Usual Care | Difference in Rate | p Value | ||||||||
| % BGs <40 mg/dL | 0.02% | 0.44% |
95.5% less with eGMS® |
<0.01 | ||||||||
| % BGs <54 mg/dL | 0.08% | 1.02% |
92.2% less with eGMS® |
<0.01 | ||||||||
| % BGs <70 mg/dL | 0.32% | 2.44% |
86.9% less with eGMS® |
<0.01 | ||||||||
| % BGs >250 mg/dL | 7.00% | 10.10% |
30.7% less with eGMS® |
<0.01 | ||||||||
| % BGs 70-180 mg/dL | 69.80% | 66.34% |
5.2% more with eGMS® |
<0.01 | ||||||||
With a continual influx of new resident physicians from both Emory
University School of Medicine and Morehouse
School of Medicine, systemization with Glytec’s technology has
proven a valuable teaching mechanism, especially given Grady Hospital is
the primary destination for many of Georgia’s most complex cases.
“This study demonstrated that personalization of insulin therapy with an
evidence-based system’s approach is superior to usual care in improving
glycemic control for our critical care patients,” said Dr.
Guillermo Umpierrez, Professor of Medicine in the Division of
Endocrinology and Metabolism at Emory University School of Medicine and
Chief of Diabetes and Endocrinology at Grady Hospital.
Dr. Jordan Messler, Executive Director of Quality Initiatives at Glytec,
adds: “We are pleased to see that Grady Hospital continues to experience
clinical excellence with eGMS® and continues to see outcomes
improvements. The results of this new study, which reflect on data from
the initial two-year period post-implementation, are consistent with the
results of an initial
study published January 2018 in the Journal of Diabetes Science and
Technology, which looked at data over the first four months
post-implementation.”
About Glytec
Founded in 2006, Glytec is the pioneer of
digital therapeutics, improving the lives of people with diabetes by
making insulin a more effective and accessible option for millions
unable to achieve their treatment goals. The company’s patented
eGlycemic Management System® is the only FDA-cleared
software-as-a-medical-device (SaMD) platform to enable the mass
personalization of insulin across the continuum of care: inpatient,
outpatient and virtual settings alike. Glytec offers several
comprehensive programs combining evidence-based decision support
technologies with expert professional services proven to aid providers
in achieving best practices and standardization while reducing
hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost.
The company has offices in Waltham, Massachusetts and Greenville, South
Carolina. For more information visit www.glytecsystems.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005878/en/